The discovery and validation of the target set off a race among pharmaceutical and biotech companies [REF].
Alirocumab was discovered by Regeneron Pharmaceuticals using its "VelocImmune" mouse,[REF] in which many of the genes coding for antibodies have been replaced with human genes [REF].